Skip directly to content


  1. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-1818.
  2. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2007;8(3):11-28.
  3. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
  4. Smith SC Jr, Collins A, Ferrari R, et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Circulation. 2012;126(3);2769-2775.
  5. Organización Mundial de la Salud. Global atlas on cardiovascular disease prevention and control. Consultado por última vez el 22 de septiembre de 2014.
  6. Weaver J. Insights into how calcium forms plaques in arteries pave the way for new treatments for heart disease. PLoS Biol. 2013;11(4):e1001533.
  7. Early J. Comprehensive management of cardiometabolic risk factors. Clin Cornerstone. 2007;8(3):69-80.
  8. Davis NE. Atherosclerosis--an inflammatory process. J Insur Med. 2005;37(1):72-75.
  9. Organización Mundial de la Salud. Consultado por última vez el 3 de julio de 2014.
  10. Alsheikh-Ali AA, Omar MI, Raal FJ, et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East cardiovascular epidemiological (ACE) study. PLoS ONE. 2014;9(8):e102830.
  11. Wang S, Xu L, Jonas J, et al. Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS ONE. 6(3):e17326.
  12. Organización Mundial de la Salud. Oficina regional de la OMS. Consultado por última vez el 3 de julio de 2014.
  13. Organización Mundial de la Salud. Global Health Observatory: raised cholesterol. Consultado por última vez el 3 de julio de 2014.
  14. Ford ES, Li C, Pearson WS, Zhao G, Mokdad AH. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol. 2010;140(2):226-235.
  15. Hermans MP, Castro Cabezas M, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010;26(2):445-454.
  16. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207-213.
  17. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;Nov 7. pii: S0735-1097(13)06028-2.
  18. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Consultado por última vez el 22 de septiembre de 2014.
  19. QRISK(R)-2014 Risk Calculator. Consultado por última vez el 22 de septiembre de 2014.
  20. Sahebkar A. Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082-98.
  21. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Lancet. 2005;366(9493):1267-1278.
  22. Raymond H, Cho L, Rocco M, Hazen SL. New cholesterol guidelines: worth the wait? Cleveland Clin J Med. 2014; 81(1):11-19.
  23. Sever PS, Dahlof B, Poulter NR, et al, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
  24. Colhoun HM, Betteridge DJ, Durrington PN, for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364: 685-696.
  25. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-1504.
  26. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-2445.
  27. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44(9):1772-1779.
  28. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
  29. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
  30. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994; 308(6925):367-372.
  31. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011;27(4):821-833.